{"id":125,"date":"2026-01-26T04:42:57","date_gmt":"2026-01-26T04:42:57","guid":{"rendered":"https:\/\/wpbmd.in\/blog\/?p=125"},"modified":"2026-01-26T05:06:57","modified_gmt":"2026-01-26T05:06:57","slug":"the-quiet-power-of-defaults-by-satish-dandekar","status":"publish","type":"post","link":"https:\/\/wpbmd.in\/blog\/the-quiet-power-of-defaults-by-satish-dandekar\/","title":{"rendered":"The Quiet Power of Defaults (By Satish Dandekar)"},"content":{"rendered":"\n

The Quiet Power of Defaults<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Why Strong Brands Refuse to Move<\/strong><\/p>\n\n\n\n

Author: Satish Dandekar<\/mark><\/strong><\/p>\n\n\n\n

In an ideal world, the best product should always win. Most management thinking is built on this assumption\u2014that better features, sharper positioning, stronger execution, or higher budgets will eventually defeat competition. Yet real markets often ignore this logic. Well-funded challengers fail to dislodge incumbents. Clearly differentiated products struggle to gain traction. And strong brands continue to dominate long after visible differences have narrowed.<\/p>\n\n\n\n

The Indian pharmaceutical market has many such examples. In almost all therapy areas, several brands of the same molecule coexist, similar in quality and price. On paper, competition is intense and fluid. In reality, a handful of brands dominate prescriptions, while many others fight endlessly for marginal share or even survival.<\/p>\n\n\n\n

This raises a fundamental question: why do strong brands refuse to get replaced?<\/strong><\/p>\n\n\n\n

The prescription reflex<\/strong><\/p>\n\n\n\n

The answer begins in a busy clinic. The outpatient department is crowded, patients are waiting, and time is limited. Once the diagnosis is made, the prescription is written almost automatically. There is no conscious comparison of brands, no weighing of studies, and no deliberation over price differentials. One brand flows onto the prescription pad.<\/p>\n\n\n\n

This speed is not only about the doctor\u2019s cognitive load; it is also shaped by the patient sitting across the table. Patients are often anxious about their illness and acutely sensitive to the doctor\u2019s behaviour. Visible hesitation or prolonged deliberation can amplify that anxiety, making the condition appear more serious than it is, or even raising doubts about the doctor\u2019s competence. Doctors know this well. Decisiveness, therefore, is not just a matter of efficiency\u2014it is a signal of reassurance and professional confidence.<\/p>\n\n\n\n

Behavioural economist Prof. Daniel Kahneman describes this mode of decision-making as \u2018System 1 thinking\u2019\u2014fast, intuitive, and automatic. Prescribing in a busy clinic operates largely in this mode. Under time pressure, emotional scrutiny from patients, and clinical responsibility, doctors default to brands that feel familiar, safe, and easy to justify, rather than engaging in slow, analytical comparison.<\/p>\n\n\n\n

This reveals a fundamental truth about decision-making in professional settings: when the moment demands speed and confidence, memory and habit <\/strong>trump analysis. The prescription reflex is not careless behaviour; it is an adaptive response to cognitive limits, patient expectations, and perceived risk. Brands that occupy the doctor\u2019s System 1 mind are not actively chosen in that moment; they are simply retrieved and written.<\/em><\/p>\n\n\n\n

From a management perspective, this challenges a deeply held belief: that competitive displacement is primarily a function of persuasion.<\/p>\n\n\n\n

The myth of equal competition<\/strong><\/p>\n\n\n\n

Most pharmaceutical companies deploy similar tools. They have a field force, inputs like samples, CRM programs, conferences, and scientific material. On the surface, the playing field looks level. Yet outcomes are not.<\/p>\n\n\n\n

This mismatch tells us that competitive failure is rarely about lack of effort. It is about misunderstanding how advantage works in habit-driven markets. Managers often respond to stagnation by increasing intensity\u2014more calls, more messages, more pressure. But habits do not respond to pressure. They respond to repetition in a stable context. Beyond a point, more persuasion produces diminishing returns.<\/p>\n\n\n\n

Guardrails are not a preference<\/strong><\/p>\n\n\n\n

Before a brand can even be considered, it must pass basic guardrails: regulatory approval, guideline acceptability, availability in trade, affordability, and, in some cases, institutional permissions such as formularies. Brands outside these boundaries are not rejected\u2014they are simply invisible.<\/p>\n\n\n\n

However, once several brands clear these guardrails, they stop differentiating. Continuing to compete here may be a strategic error.<\/p>\n\n\n\n

Guardrails determine eligibility, not preference<\/strong>.<\/strong> Real competition begins only after these conditions are met.<\/p>\n\n\n\n

The gateway to habit<\/strong><\/p>\n\n\n\n

Strong brands are rarely born broad. They become strong by being used repeatedly in one familiar situation<\/strong>\u2014a gateway. This might be a routine infection, a standard initiation therapy, or a common outpatient scenario. E.g. \u2018Augmentin\u2019 in Chronic Suppurative Otitis Media. (CSOM).<\/p>\n\n\n\n

Within this narrow space, repetition builds confidence. Outcomes accumulate. Memory strengthens. Managers often resist such focus, fearing missed opportunities. They want the brand to stand for multiple indications and benefits from the start. <\/p>\n\n\n\n

But cognitive science is clear: Narrow entry strengthens recall. Broad entry dilutes it.<\/mark><\/strong><\/p>\n\n\n\n

Brands that try to be everything to everyone often fail to lodge firmly in the mind. Those who anchor themselves to a single gateway are recalled faster and prescribed with greater confidence.<\/p>\n\n\n\n

Spillover happens naturally<\/strong><\/p>\n\n\n\n

Once a brand proves itself in its gateway, something interesting happens. Doctors begin using it in adjacent situations\u2014not because they were persuaded by new messaging, but because their confidence threshold has been crossed. This spillover is organic. It is growth driven by experience, not promotion. The brand moves from being an option to becoming a default.<\/p>\n\n\n\n

Brand entrenchment deepens as clinical risk increases. In high-stakes conditions\u2014chronic diseases, life-threatening illnesses, or medico-legally sensitive situations\u2014switching becomes especially difficult.<\/p>\n\n\n\n

Once a brand proves itself in a high-risk context, it becomes psychologically entrenched.<\/p>\n\n\n\n

Why challengers struggle<\/strong><\/p>\n\n\n\n

Most challengers respond by increasing persuasion- more data, stronger claims, higher frequency. Incumbents, however, are protected by something far more durable: cumulative reassurance<\/strong>.<\/p>\n\n\n\n

Over time, strong brands cross three invisible thresholds:<\/p>\n\n\n\n